Crescent Sterling Ltd. Has $2.43 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Crescent Sterling Ltd. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,309 shares of the medical research company’s stock after purchasing an additional 438 shares during the period. Amgen accounts for approximately 2.5% of Crescent Sterling Ltd.’s investment portfolio, making the stock its 12th biggest holding. Crescent Sterling Ltd.’s holdings in Amgen were worth $2,426,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in AMGN. Matrix Trust Co lifted its holdings in shares of Amgen by 306.2% during the fourth quarter. Matrix Trust Co now owns 459 shares of the medical research company’s stock worth $120,000 after buying an additional 346 shares in the last quarter. Aprio Wealth Management LLC increased its position in Amgen by 7.9% during the fourth quarter. Aprio Wealth Management LLC now owns 1,244 shares of the medical research company’s stock worth $324,000 after acquiring an additional 91 shares during the period. Czech National Bank raised its stake in Amgen by 6.5% in the 4th quarter. Czech National Bank now owns 116,548 shares of the medical research company’s stock worth $30,377,000 after purchasing an additional 7,089 shares in the last quarter. Graypoint LLC boosted its holdings in Amgen by 42.1% in the 4th quarter. Graypoint LLC now owns 7,339 shares of the medical research company’s stock valued at $1,913,000 after purchasing an additional 2,175 shares during the period. Finally, HBW Advisory Services LLC grew its position in shares of Amgen by 1.0% during the 4th quarter. HBW Advisory Services LLC now owns 8,559 shares of the medical research company’s stock worth $2,231,000 after purchasing an additional 88 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $262.23 on Monday. The company has a market capitalization of $140.96 billion, a PE ratio of 33.58, a P/E/G ratio of 2.91 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a fifty day simple moving average of $279.10 and a 200 day simple moving average of $308.66.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the prior year, the business earned $4.96 EPS. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 121.90%.

Analyst Ratings Changes

AMGN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Redburn Partners decreased their price target on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Barclays upped their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Finally, Sanford C. Bernstein started coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.